Biotech Values

[DonShimoda]

dough, it'll be interesting to see how ariad designs a phase 2/3 trial for AP534. I'm assuming it'll be similar to nilotinib and dasatinib (eg interventional, open label) when they went directly to a phase 2/3 registration trial. What will be interesting is the degree to which ariad will target enrollment of patients with the T315I mutation. Looking at the data from today's abstract one could conclude that AP534 is equally as potent in chronic CML patients with no mutations.